City Therapeutics Raised $100 Million for RNAi Tech

The Cambridge-based biotech firm secured new funding to advance its pipeline toward clinical development.

Updated on Oct. 12, 2026 in Biotech

City Therapeutics Raised $100 Million for RNAi Tech

Live Poll

Do you support biotechnology startups relying on major pharmaceutical companies to fund their drug development?

Cambridge-based City Therapeutics raised $100 million in financing on June 9, 2026. This latest round brings the company's total disclosed funding to $235 million.

Why it matters

The capital is designated to move the company's RNAi programs into clinical development. The firm seeks to pioneer therapies that target tissues beyond the liver.

The company uses chemically modified small interfering RNAs designed to silence specific disease-causing genes. Their platform integrates this engineering with proprietary delivery technology developed through a $1 billion partnership with Biogen.

The players

City Therapeutics

This Cambridge-based biotechnology company specializes in developing small interfering RNA therapies to silence disease-causing genes.

Biogen

This global biotechnology company entered into a strategic collaboration with City Therapeutics to co-develop RNAi delivery technologies.

Andrew Orth

He serves as the Chief Executive Officer and Director of City Therapeutics, having assumed the leadership role in January 2025.

The details

Founded in October 2024, the company focuses on advancing its pipeline of RNA interference therapies. Since its inception, the firm has leveraged its proprietary delivery systems to improve the reach of genetic medicine.

October 2024: Company launched publicly with $135 million Series A.
January 2025: Andrew Orth was appointed as CEO and Director.
May 28, 2025: Strategic collaboration with Biogen was announced.
June 9, 2026: $100 million in additional financing closed.

The Tech Race

This development follows the broader trend of increased capital allocation toward RNAi therapy platforms designed to bypass traditional delivery limitations. It positions the company within the highly competitive field of genetic medicine where firms race to develop therapies that can reach diverse organ systems.

The progress of these RNAi therapies could eventually provide patients with new treatment options for complex diseases that were previously unreachable by traditional genetic medicines. Investors and stakeholders should monitor the firm's progress toward its initial Phase I clinical trial milestones.

The takeaway

The successful funding round demonstrates ongoing investor confidence in genetic silencing technologies. The firm's next major test will be successfully transitioning its lab-based RNAi designs into successful Phase I clinical trials.